$BDTX News

What's Going On With Black Diamond Therapeutics Stock Tuesday?

Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 Study

Black Diamond Therapeutic Q1 EPS $(0.16) Misses $(0.03) Estimate

BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11

Implied Volatility Surging for Black Diamond Therapeutics Stock Options

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond To Present Phase 2 Data Of Silevertinib In Recurrent EGFRm NSCLC Patients And Trial-In-Progress Poster On Randomized Phase 2 Trial Of Silevertinib In EGFRvIII-Positive GBM At 2026 ASCO

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026

Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program

Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

Black Diamond: Q4 Earnings Snapshot

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Black Diamond Therapeutic Q4 EPS $(0.27) Misses $(0.19) Estimate

Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker

Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People Officer

Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?